WO1998056901A3 - Live attenuated vaccines - Google Patents

Live attenuated vaccines Download PDF

Info

Publication number
WO1998056901A3
WO1998056901A3 PCT/GB1998/001683 GB9801683W WO9856901A3 WO 1998056901 A3 WO1998056901 A3 WO 1998056901A3 GB 9801683 W GB9801683 W GB 9801683W WO 9856901 A3 WO9856901 A3 WO 9856901A3
Authority
WO
WIPO (PCT)
Prior art keywords
live attenuated
attenuated vaccines
bacterium
homologue
fur gene
Prior art date
Application number
PCT/GB1998/001683
Other languages
French (fr)
Other versions
WO1998056901A2 (en
Inventor
Thomas John Baldwin
Saverio Peter Borriello
Helen Mary Palmer
Original Assignee
Medical Res Council
Thomas John Baldwin
Saverio Peter Borriello
Helen Mary Palmer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Res Council, Thomas John Baldwin, Saverio Peter Borriello, Helen Mary Palmer filed Critical Medical Res Council
Priority to JP50189199A priority Critical patent/JP2002511752A/en
Priority to CA002292900A priority patent/CA2292900A1/en
Priority to AU80268/98A priority patent/AU745003B2/en
Priority to EP98928436A priority patent/EP0996712A2/en
Priority to BR9809974-4A priority patent/BR9809974A/en
Publication of WO1998056901A2 publication Critical patent/WO1998056901A2/en
Publication of WO1998056901A3 publication Critical patent/WO1998056901A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

An attenuated bacterium in which the native fur gene, or homologue thereof, is modified such that the expression of the fur gene product, or homologue thereof, is regulated independently of the iron concentration in the environment of the bacterium, is suitable for use as a live vaccine. The bacterium may be, in particular, Neisseria meningitidis.
PCT/GB1998/001683 1997-06-09 1998-06-09 Live attenuated vaccines WO1998056901A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP50189199A JP2002511752A (en) 1997-06-09 1998-06-09 Live attenuated vaccine
CA002292900A CA2292900A1 (en) 1997-06-09 1998-06-09 Live attenuated vaccines
AU80268/98A AU745003B2 (en) 1997-06-09 1998-06-09 Live attenuated vaccines
EP98928436A EP0996712A2 (en) 1997-06-09 1998-06-09 Live attenuated vaccines
BR9809974-4A BR9809974A (en) 1997-06-09 1998-06-09 Live attenuated vaccines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9711964.8A GB9711964D0 (en) 1997-06-09 1997-06-09 Live attenuated vaccines
GB9711964.8 1997-06-09

Publications (2)

Publication Number Publication Date
WO1998056901A2 WO1998056901A2 (en) 1998-12-17
WO1998056901A3 true WO1998056901A3 (en) 1999-03-18

Family

ID=10813847

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1998/001683 WO1998056901A2 (en) 1997-06-09 1998-06-09 Live attenuated vaccines

Country Status (6)

Country Link
EP (1) EP0996712A2 (en)
JP (1) JP2002511752A (en)
AU (1) AU745003B2 (en)
CA (1) CA2292900A1 (en)
GB (1) GB9711964D0 (en)
WO (1) WO1998056901A2 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9823978D0 (en) 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
US10967045B2 (en) 1998-11-02 2021-04-06 Secretary of State for Health and Social Care Multicomponent meningococcal vaccine
GB9918319D0 (en) * 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB9929923D0 (en) * 1999-12-17 2000-02-09 Baldwin Thomas J Antigen preparations
GB0011108D0 (en) * 2000-05-08 2000-06-28 Microscience Ltd Virulence gene and protein and their use
GB0012079D0 (en) * 2000-05-18 2000-07-12 Microscience Ltd Virulence gene and protein, and their use
BRPI0112928B1 (en) 2000-07-27 2017-08-29 Children's Hospital & Research Center At Oakland A composition comprising preparations comprising outer membrane vesicles (OMV), microvesicles (MV) or both MVO and MV
US7045122B2 (en) 2000-11-16 2006-05-16 Akzo Nobel N.V. Salmonella vaccine
EP1499191B1 (en) 2002-04-15 2012-05-09 Washington University in St. Louis Regulated attenuation of live vaccines to enhance cross protective immunogenicity
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
ES2411080T3 (en) 2003-01-30 2013-07-04 Novartis Ag Injectable vaccines against multiple serogroups of meningococci
GB0308691D0 (en) * 2003-04-07 2003-05-21 Xenova Res Ltd Vaccine preparations
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
EP2682126B1 (en) 2005-01-27 2016-11-23 Children's Hospital & Research Center at Oakland GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
BR122016015627A2 (en) 2007-10-19 2018-10-30 Novartis Ag kit, lyophilized antigen composition and method for preparation of an immunogenic composition
US8685413B2 (en) * 2008-01-30 2014-04-01 Universitat Autonoma De Barcelona Heterologous protection against Pasteurella multocida provided by P. multocida fur cells and the outer-membrane protein extracts thereof
RU2475496C2 (en) 2008-02-21 2013-02-20 Новартис Аг MENINGOCOCCAL fHBP POLYPEPTIDES
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
CA2747340A1 (en) 2008-12-17 2010-06-24 Novartis Ag Meningococcal vaccines including hemoglobin receptor
AU2010258677B2 (en) 2009-06-10 2016-10-06 Glaxosmithkline Biologicals S.A. Benzonaphthyridine-containing vaccines
WO2011024071A1 (en) 2009-08-27 2011-03-03 Novartis Ag Adjuvant comprising aluminium, oligonucleotide and polycation
JP2013502918A (en) 2009-08-27 2013-01-31 ノバルティス アーゲー Hybrid polypeptide comprising Neisseria meningitidis fHBP sequence
JO3257B1 (en) 2009-09-02 2018-09-16 Novartis Ag Compounds and compositions as tlr activity modulators
DK2459216T3 (en) 2009-09-02 2013-12-09 Novartis Ag IMMUNOGENIC COMPOSITIONS INCLUDING TLR ACTIVITY MODULATORS
CN102724988B (en) 2009-09-30 2014-09-10 诺华股份有限公司 Expression of meningococcal fHBP polypeptides
WO2011051893A1 (en) 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
SG10201501980SA (en) 2009-12-15 2015-05-28 Novartis Ag Homogeneous suspension of immunopotentiating compounds and uses thereof
CN102802662A (en) 2010-03-18 2012-11-28 诺华有限公司 Adjuvanted vaccines for serogroup B meningococcus
CA2792938C (en) 2010-03-23 2018-07-31 Irm Llc Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc.
BR112016019735A2 (en) 2014-02-28 2017-10-17 Glaxosmithkline Biologicals Sa fhbp, polypeptide, plasmid or other nucleic acid, host cell, membrane vesicles, and immunogenic composition
WO2017136947A1 (en) 2016-02-10 2017-08-17 Moraes Trevor F Slam polynucleotides and polypeptides and uses thereof
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987002678A1 (en) * 1985-10-24 1987-05-07 State Of Oregon, Acting By And Through The Oregon Major iron-regulated protein of neisseria gonorrhoeae and its use as vaccine
EP0322237A1 (en) * 1987-12-23 1989-06-28 The Wellcome Foundation Limited Vaccines
WO1994005326A1 (en) * 1992-09-04 1994-03-17 University Of Saskatchewan Novel bacterial vaccines using vaccine strains of pathogenic bacteria

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987002678A1 (en) * 1985-10-24 1987-05-07 State Of Oregon, Acting By And Through The Oregon Major iron-regulated protein of neisseria gonorrhoeae and its use as vaccine
EP0322237A1 (en) * 1987-12-23 1989-06-28 The Wellcome Foundation Limited Vaccines
WO1994005326A1 (en) * 1992-09-04 1994-03-17 University Of Saskatchewan Novel bacterial vaccines using vaccine strains of pathogenic bacteria

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PINTOR M. ET AL.: "Blocking of iron uptake from transferrin by antibodies against the transferrin binding proteins in Neisseria meningitidis", MICROBIAL PATHOGENESIS, vol. 20, no. 3, 1996, pages 127 - 139, XP002085216 *

Also Published As

Publication number Publication date
AU8026898A (en) 1998-12-30
EP0996712A2 (en) 2000-05-03
CA2292900A1 (en) 1998-12-17
WO1998056901A2 (en) 1998-12-17
GB9711964D0 (en) 1997-08-06
JP2002511752A (en) 2002-04-16
AU745003B2 (en) 2002-03-07

Similar Documents

Publication Publication Date Title
WO1998056901A3 (en) Live attenuated vaccines
DE69841807D1 (en) NEISSERIAL ANTIGENE
ZA935869B (en) Aqueous dispersions of zein and controlled release coatings derived therefrom
NZ515935A (en) Combination Neisserial compositions and vaccines for the prevention of infections due to Neisseria bacteria such as meningococcal meningitis
NZ508366A (en) Neisseria meningitidis antigens and compositions
DE60044005D1 (en) 85 kDa Antigen of Neisseria
CY1107950T1 (en) NAVIGATION VACCINE COMPOSITIONS AND METHODS
DE3854213D1 (en) Analogs of the subunit of Bordetella toxin derived from recombinant DNA.
DE69322092D1 (en) NEW BACTERIAL VACCINES USING VACCINE STRAINS FROM PATHOGENIC BACTERIA
GB9806449D0 (en) Attenuated bacteria useful in vaccines
PL344851A1 (en) Bacterium of salmonella type and vaccine containing that bacterium for protecting animals against salmonellosis and method of obtaining such vaccine
DK0892054T3 (en) Clostridium perfringens vaccine
NZ295877A (en) A vaccine comprising the helicobacter bacterium and its use
ZA200002615B (en) Live attenuated bacteria for use in a vaccine.
BR9809974A (en) Live attenuated vaccines
AU6761301A (en) Adjuvant composition comprising fha protein or fragment of fha protein in free form
AU2010201539B2 (en) Anti-bacterial vaccine compositions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2292900

Country of ref document: CA

Ref country code: CA

Ref document number: 2292900

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 80268/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/011431

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1998928436

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09445788

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1998928436

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 80268/98

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1998928436

Country of ref document: EP